Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03424005 · ClinicalTrials.gov registry record · Phase 1
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
A Phase 1 study of Metastatic Breast Cancer, sponsored by Hoffmann-La Roche.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 792
- Enrollment target
- 20
- Study locations
NCT03424005 is a Phase 1 study of Metastatic Breast Cancer that is actively recruiting participants, run by Hoffmann-La Roche. The registered enrollment target is 792 participants, above the 199-participant average among 139 other Metastatic Breast Cancer trials with a reported enrollment target (298% higher). The trial reports 20 study locations across 11 states.
The verdict
NCT03424005, a Phase 1 study of Metastatic Breast Cancer, is actively recruiting participants, sponsored by Hoffmann-La Roche.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 792 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is an umbrella study evaluating the efficacy and safety of multiple treatment combinations in participants with metastatic or inoperable locally advanced breast cancer. The study will be performed in two stages. During Stage 1, six cohorts will be enrolled in parallel in this study: Cohort 1 will consist of programmed death-ligand 1 (PD-L1)-positive participants who have received no prior systemic therapy for metastatic or inoperable locally advanced triple-negative breast cancer (TNBC) (first-line \[1L\] PD-L1+ cohort). Cohort 2 will consist of participants who had disease progression during or following 1L treatment with chemotherapy for metastatic or inoperable locally-advanced TNBC and have not received cancer immunotherapy (CIT) (second-line \[2L\] CIT-naïve cohort). Cohort 3, 5, and 6 will consist of participants with locally advanced or metastatic hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-negative disease with one or more PIK3CA mutations. Cohort 4 will consist of participants with locally advanced or metastatic HER2+ /HER2-low disease with one or more PIK3CA mutations who had disease progression on standard-of-care therapies (HER2+ /HER2-low cohort). In each cohort, eligible participants will initially be assigned to one of several treatment arms (Stage 1). During Stage 2, participants in the 2L CIT-naïve cohort who experience disease progression, loss of clinical benefit, or unacceptable toxicity during Stage 1 may be eligible to continue treatment with a different treatment combination, provided Stage 2 is open for enrollment and all eligibility criteria are met.
Conditions Studied
Interventions
- DRUG Bevacizumab
- DRUG Capecitabine
- DRUG Atezolizumab
- DRUG Ipatasertib
- DRUG SGN-LIV1A
Study Locations (20)
Tennessee
- Tennessee Oncology - Chattanooga Oncology & Hematology Associates - Chattanooga
- The West Clinic - Germantown
- Tennessee Oncology PLLC - Nashville
- Vanderbilt University Medical Center - Nashville
California
- City of Hope - Duarte
- University of California San Diego Medical Center - La Jolla
- Stanford Cancer Institute - Stanford
New Jersey
- Hackensack Univ Medical Center - Hackensack
- Regional Cancer Care Associates, LLC - Howell Township
- Rutgers Cancer Institute of New Jersey - New Brunswick
Pennsylvania
- Thomas Jefferson University Hospital - Philadelphia
- University of Pittsburgh Medical Center - Pittsburgh
Other
- Centre Léon Bérard - Lyon
- Institut régional du Cancer Montpellier - Montpellier
Colorado
- Rocky Mountain Cancer Center - Longmont - Longmont
Florida
- H. Lee Moffitt Cancer Center and Research Inst. - Tampa
New York
- NYU Langone Medical Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 792 participants |
| Start Date | 2018-03-30 |
| Est. Completion | 2030-09-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03424005
The ClinicalTrials.gov registry entry for NCT03424005 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 792 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 199-participant average among 139 other Metastatic Breast Cancer trials with a reported enrollment target (298% higher). The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Metastatic Breast Cancer appearing as the primary indexed condition, and to 5 interventions - of which Bevacizumab is the first listed.
NCT03424005 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Tennessee, California, New Jersey.
Frequently Asked Questions
What is clinical trial NCT03424005 about?
NCT03424005 is a clinical study titled "A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer". This is an umbrella study evaluating the efficacy and safety of multiple treatment combinations in participants with metastatic or inoperable locally advanced breast cancer. The study will be performed in two stages. During Stage 1, six cohorts will be enrolled in parallel in this study: Cohort 1 ...
What is the current status of trial NCT03424005?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 792 participants. The study started on 2018-03-30. Estimated completion is 2030-09-30.
What conditions does trial NCT03424005 study?
This clinical trial studies the following conditions: Metastatic Breast Cancer.
What interventions are being tested in trial NCT03424005?
The interventions under investigation include: Bevacizumab (DRUG), Capecitabine (DRUG), Atezolizumab (DRUG), Ipatasertib (DRUG), SGN-LIV1A (DRUG).
Who is sponsoring clinical trial NCT03424005?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03424005 being conducted?
This trial has 20 study locations across California, Colorado, Florida, New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
RECRUITING · Phase 1
-
Ribociclib&Belinostat In Patients w Metastatic Triple Neg Breast Cancer & Recurrent Ovarian Cancer w Response Prediction By Genomics
RECRUITING · Phase 1
-
Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer
RECRUITING · Phase 1
-
PRE-I-SPY Phase I/Ib Oncology Platform Program
RECRUITING · Phase 1
-
A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer
RECRUITING · Phase 1
-
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.